Rational approaches to antithrombotic therapy in patients with acute coronary syndromes and non-valvular atrial fibrillation (adapted from the European Congress of Cardiology 2014)

Cover Page

Cite item

Full Text

Abstract

The article deals with the current understanding of the prevalence and clinical significance of atrial fibrillation in patients with acute coronary syndrome. We have described the approaches in the treatment of this group of patients using antithrombotic therapy. On the basis of consensus papers released by the European Society of Cardiology 2014 the special place was taken by the novel oral anticoagulants as an alternative to warfarin for patients with acute coronary syndrome and atrial fibrillation. We showed the results of clinical studies and statistical subanalysis, which could be used as the basis for application of novel oral anticoagulants as a part of triple antithrombotic therapy, including dabigatran 110 mg twice daily.

About the authors

O. L Barbarash

Scientific-Research Institute for Complex Issues of Cardiovascular Disease; Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation

Email: Olb61@mail.ru
д-р мед. наук, проф., дир. ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний, зав. каф. кардиологии и сердечно-сосудистой хирургии ГБОУ ВПО КемГМА 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6

V. V Kashtalap

Scientific-Research Institute for Complex Issues of Cardiovascular Disease; Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation

Email: v_kash@mail.ru
канд. мед. наук, зав. лаб. патофизиологии мультифокального атеросклероза ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний, доц. каф. кардиологии и сердечно-сосудистой хирургии ГБОУ ВПО КемГМА 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6

References

  1. Чазов Е.И. Пути снижения смертности от сердечно - сосудистых заболеваний. Терапевтический архив. 2008; 8: 11-6.
  2. Здравоохранение в России. 2009: статистический сборник. М.: Росстат, 2009.
  3. Оганов Р.Г., Калинина А.М., Концевая А.В. Экономический ущерб от сердечно - сосудистых заболеваний в Российской Федерации. Кардиоваскуляр. терапия и профилактика. 2011; 4: 4-9.
  4. Steg G, James S.K, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 2012; 33: 2569-19.
  5. Эрлих А.Д., Харченко М.С., Барбараш О.Л. и др. Степень приверженности к выполнению руководств по лечению острого коронарного синдрома в клинической практике российских стационаров и исходы в период госпитализации (данные регистра «РЕКОРД-2»). Кардиология. 2013; 1: 14-22.
  6. Dewilde W.J, Oirbans T, Verheugt F.W et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open - label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107-15. doi: 10.1016/S0140-6736(12) 62177-1.
  7. Subherwal S, Bach R.G et al. Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction. Circulation 2009; 119: 1873-882.
  8. Затейщиков Д.А., Исаева М.Ю. Вопросы организации лечения антикоагулянтами. Клин. практика. 2012; 3 (11): 51-62.
  9. Abu-Assi E, Raposeiras-Roubín S, García-Acuña J.M, González-Juanatey J.R. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol 2014; 6 (11): 1140-8.
  10. Верткин А.Л., Вовк Е.И., Наумов А.В. и др. Лечение и профилактика поражений слизистой оболочки желудочно - кишечного тракта в терапевтической практике. Клин. перспективы гастроэнтерологии, гепатологии. 2009; 1: 35-41.
  11. Mehta S.R et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012; 60: 2490-9.
  12. Schmitt J et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038-45.
  13. Rahman F, Kwan G.F, Benjamin E.J. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology 2014; 11: 639-54. doi: 10.1038/nrcardio.2014.118.
  14. Rene A.G, Généreux P, Ezekowitz M et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol 2014; 113: 236-42.
  15. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
  16. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. The ACTIVE Investigators. N Engl J Med 2009; 360: 2066-78.
  17. Lamberts M et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention Circulation 2012; 126: 1185-93.
  18. Potpara T.S, Lane D.A, Lip G.Y.H. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace 2015; 17 (4): 507-8.
  19. Connolly S.J et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12): 1139-51.
  20. Lip G et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J 2014; doi: 10.1093/eurheartj/ehu298.
  21. Dans A.L et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-40.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies